



VGO NORTE INTERNATIONAL GU DEBATES

8th - 9th

OCTOBER
2026



X #GonorteGUDebates

VENUE

PARADOR DE LIMPIAS
Fuente del Amor s/n,
39820, Limpías (Cantabria)

ORGANIZED BY



GONORTE
Grupo Oncológico



PRELIMINAR SCIENTIFIC PROGRAMME

THURSDAY, OCTOBER 8th

08:30	REGISTRATION
09:00-09:10	OPENING Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander Dra. Nuria Lainez, Medical Oncology Department, Hospital Universitario de Navarra, Pamplona
09:10-11:50	SESSION 1. NON-MUSCLE INVASIVE BLADDER CANCER: ARE NEW TREATMENTS READY FOR PRIME TIME? Chairs: Dr. Daniel Castellano, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid Dr. José Rubio, Urology Department, Hospital Vithas Valencia 9 de Octubre
09:15-09:30	Clinical Vignette
09:30-09:45	NMIBC: What do I need to know to understand drug development in this setting? Dr. Jozefina Casuscelli, Urology Department, LMU University Hospital, Munich, Germany
09:45-10:00	New I.O. based treatments are ready for prime time in BCG naïve NMIBC patients Dr. Javier Puente, Genitourinary Medical Oncology Department, Hospital Universitario San Carlos, Madrid
10:00-10:15	New IO. based treatments are not ready for prime time in BCG naïve NMIBC patients Dr. Félix Guerrero, Urology Department, Hospital Universitario 12 de Octubre, Madrid
10:15-10:30	Radiotherapy-based treatments as an emerging strategy in HR NMIBC Dr. Xavier Maldonado, Radiology Department, Vall d'Hebron Barcelona Hospital
10:30-10:45	Intravesical drug-delivery systems in BCG-naïve disease: evidence and limitations Dr. Bernardo Herrera, Urology Department, Hospital Universitario Virgen de la Victoria, Málaga
10:45-11:15	Discussion
11:15-11:50	Coffee Break ☕



11:50-13:20

SESSION 2. MUSCLE INVASIVE BLADDER CANCER: APPROACHING A CLASSIC DISEASE IN A NEW ERA

Chairs:

Dra. Elena Sevillano, Medical Oncology Department, Centro Integral Oncológico Clara Campal HM CIOCC, Madrid

Dr. Jerónimo Barrera, Urological Radiology Department, Hospital Clínico San Carlos, Madrid

11:50-12:05

Clinical Vignette

12:05-12:20

Do I have to convince my radiologist to perform MRI in MIBC?

From its role in initial staging to potential biomarker of response

Dr. Richard Mast, Radiology Department, Vall d'Hebron Barcelona Hospital

12:20-12:35

Variant histologies in MIBC: Which ones, how often and how much should condition my perioperative treatment selection?

Dra. Ainara Azueta, Pathology Department, Hospital Universitario Basurto, Bilbao

12:35-12:50

Do blood or urine biomarkers have any role in guiding perioperative treatment?

Dr. Yohan Lorient, Medical Oncology Department, Institut Gustave Roussy, Villejuif, France

12:50-13:20

Discussion

13:20-14:05

MEET THE EXPERT SYMPOSIUM

14:05-15:30

Lunch Break 🍴

15:30-17:00

SESSION 3. DEBATING BEST TREATMENT APPROACH IN MUSCLE INVASIVE BLADDER CANCER

Chairs:

Dr. Enrique Grande, Medical Oncology Department, Quirónsalud, Madrid

Dr. Mario Álvarez Maestro, Urology Department, Hospital Universitario La Paz, Madrid

15:30-15:50

Are perioperative ADC combinations the new default strategy?

Dr. Patrizia Giannatempo, Medical Oncology Department, Istituto Nazionale dei Tumori, Milan, Italy

15:50-16:10

Perioperative chemotherapy plus checkpoint inhibition: Which and to whom in 2026?

Dr. Syed A. Hussain, Medical Oncology Department, University of Sheffield, Sheffield Teaching Hospitals NHS Trust, UK



- 16:10–16:30 **What if I want to preserve my bladder? Current and future bladder sparing strategies in MBIC**
Dr. Terence Friedlander, Genitourinary Medical Oncology, University of California, San Francisco, USA
- 16:30–17:00 **Discussion**
- 17:00-17:45 **MEET THE EXPERT SYMPOSIUM**
- 17:45-18:20 **Coffee Break** ☕
- 18:20-19:05 **MEET THE EXPERT SYMPOSIUM | ADVANCED DISEASE**
Sponsored by MSD
Chair:
Dra. María José Juan Fita, Medical Oncology Department, Instituto Valenciano de Oncología, Valencia

Speakers:
Dr. Petros Grivas, Medical Oncology Department, Genitourinary Cancers Program, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Center
- 19:05-19:15 **2024 GO NORTE GRANTS**
- 19:05–19:10 **Mechanisms of resistance to immunotherapy in patients with non-urothelial histological variant metastatic urinary tract tumours (CHESSY PROJECT)**
Dr. Diego Cacho, Medical Oncology Department, Hospital Universitario. Marqués de Valdecilla – IDIVAL, Santander
- 19:10–19:15 **Prognostic and predictive value of low-density neutrophils in first-line treatment of metastatic renal cell carcinoma with immune checkpoint inhibitors**
Dr. Ibon Gurrutxaga, Medical Oncology Department, Hospital Universitario de Navarra, Pamplona
- 19:15 -19:45 **KEYNOTE LECTURE**
Treating Bladder Cancer in 2030: What does the future hold?
Dr. Petros Grivas, Medical Oncology Department, Genitourinary Cancers Program, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Center
- 19:45-19:50 **CLOSING OF THE DAY**
- 20:00 **GET TOGETHER COKTAIL AND DINNER**



FRIDAY, OCTOBER 9th

08:00- 08:15

OPENING

Dr. Ricardo Fernández, Medical Oncology Department, Hospital Universitario de Cruces, Bilbao

Dr. Carmen Santander, Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza

08:15-09:35

SESSION 4. PROSTATE CANCER

Chairs:

Dr. Miguel Ángel Climent, Medical Oncology Department, Instituto Valenciano de Oncología, Valencia

Dra. Estefania Linares, Urology Department, Hospital Universitario La Paz, Madrid

08:15-08:30

The perioperative treatment of high-risk Prostate Cancer in 2026: Where do things stand after PROTEUS?

Dr. David Lorente, Medical Oncology Department, Instituto Valenciano de Oncología, Valencia

08:30-08:45

Advanced hormone sensitive disease: Is the triplet vs doublet debate over?

Juan Francisco Rodríguez-Moreno, Medical Oncology Department, Centro Integral Oncológico Clara Campal HM CIOCC, Madrid

08:45-09:00

Optimizing androgen receptor-targeted therapy in mCRPC in 2026: Present options and near future

Dr. Charles J. Ryan, Genitourinary Medical Oncologist Department, Memorial Sloan Kettering Cancer Center, New York, USA

09:00-09:15

Positioning PARP Inhibitors in mCRPC: The 2026 Landscape

Dr. Enrique González-Billalabeitia, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

09:15 - 09:35

Discussion

09:35-10:20

MEET THE EXPERT SYMPOSIUM

10:20-10:55

Coffee Break ☕



11:00-11:47

MEET THE EXPERT SYMPOSIUM | **PLUVICTO IN mCRPC: REDEFINING THE THERAPEUTIC ALGORITHM**

Sponsored by Novartis

48 min

Chair:

Dr. Daniel Castellano, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

Dr. Iratxe Fernandez Tercero, Nuclear Medicine Department, Hospital Universitario de Cruces, Bilbao

11:00-11:03

Welcome and introduction

11:03-11:12

Positioning of Pluvicto in the therapeutic landscape of mCRPC in Spain in 2026

Dr. Naiara Sagaztibeltza, Medical Oncology Department, Hospital Universitario de Donostia, San Sebastian

11:12-11:21

Imaging-based selection criteria: the Nuclear Medicine perspective

Dr. Zulema Nogareda, Nuclear Medicine Department, Complejo Hospitalario Universitario de Santiago de Compostela

11:21 - 11:35

Pluvicto: lessons from clinical experience

Dr. Pablo Maroto, Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona

11:35-11:45

Discussion

11:45-11:47

Closing Remarks

11:50-13:05

SESSION 5. HIGH RISK LOCALIZED RENAL CANCER

Chairs:

Dr. Pablo Maroto, Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona

Dr. Mario Dominguez, Urology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

11:50-12:00

Clinical Vignette

12:00-12:15

Estimating risk after nephrectomy: Are we all in the same page? Are we overtreating?

Dr. Teresa Alonso, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid

12:15-12:30

Reshaping adjuvant treatment in 2026: Is angiogenesis back?

Dr. Dan Heng, Medical Oncology Department, Tom Baker Cancer Center & Baker Cancer Center, Calgary, Canada



12:30-12:45

I am in favor of systemic treatment first? Role of neoadjuvant treatment in high risk RCC

Dr. Axel Bex, Genitourinary Medical Oncologist Department, Amsterdam University Medical Center, The Netherlands Cancer Institute

12:45-13:05

Discussion

13.05-14:10

SESSION 6. ADVANCED RENAL CANCER AND OTHER VLH MEDIATED DISEASES

Chairs:

Dr. Jesús García Donas, Medical Oncology Department, Hospital Universitario HM Sanchinarro - Centro Integral Oncológico Clara Campal HM CIOCC, Madrid

Dr. Xavier García Del Muro, Genitourinary Medical Oncologist Department, IOB Institute of Oncology, Institut Català d'Oncologia, L'Hospitalet de Llobregat

13:05-13:20

First line mRCC: IO-IO vs IO-TKI: Is the eternal debate over?

Dr Lisa Pickering, Medical Oncology Department, The Royal Marsden NHS Foundation Trust, London, UK

13:20-13:35

**Sequencing treatments in the advanced setting:
Is it clear in 2026?**

Dr. Cristina Suárez, Medical Oncology Department, Vall d'Hebron Barcelona Hospital

13:35-13:50

Inhibiting HIF in VHL syndrome: A life changer for patients?

Dr. Guillermo De Velasco, Medical Oncology Department, Hospital 12 de Octubre, Madrid

13:50-14:10

Discussion

14:10-14:40

CLOSING LECTURE:

Curing the Incurable? Rethinking long-term disease control in advanced RCC

Dr. Dan Heng, Medical Oncology Department, Tom Baker Cancer Center & Baker Cancer Center, Calgary, Canada

14:40

CLOSING OF THE SYMPOSIUM

Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

Dr. Ricardo Fernández, Medical Oncology Department, Hospital Universitario de Cruces, Bilbao



VGO NORTE INTERNATIONAL GU DEBATES

8th-9th

OCTOBER
2026



SPONSORS

PLATINUM



SILVER



BRONZE

